AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32588429 — intervention group
Group type: EXPERIMENTAL
Intervention: PBC
Number of subjects: 495
Study 34717535 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 1 g (P group)
Number of subjects: 300
Study 34717535 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg IVI (D group)
Number of subjects: 300
Study 34717535 — intervention group
Group type: COMPARATOR
Intervention: Placebo (C group)
Number of subjects: 300
Study 32108181 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast Session
Number of subjects: 0
Study 32108181 — intervention group
Group type: COMPARATOR
Intervention: Late-evening Snack Session
Number of subjects: 0
Study 32964807 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-QSAR models (CoMFA)
Number of subjects: 26
Study 32964807 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-QSAR models (CoMSIA)
Number of subjects: 26
Study 32964807 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-QSAR models (test set)
Number of subjects: 26
Study 32964807 — intervention group
Group type: EXPERIMENTAL
Intervention: Docking studies (new designed compound C2)
Number of subjects: 26
Study 32964807 — intervention group
Group type: EXPERIMENTAL
Intervention: ADMET properties analysis
Number of subjects: 26
Study 33956703 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole (n=31), initiated at 0.125 mg 2 times a day, increased to a target of 4.5 mg/d
Number of subjects: 60
Study 33956703 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=29)
Number of subjects: 60
Study 34726501 — intervention group
Group type: EXPERIMENTAL
Intervention: Banaba (500 mg) twice a day for 12 weeks
Number of subjects: 24
Study 34726501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 32939597 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg
Number of subjects: 0
Study 32939597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35553855 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (80 min, 3 days per week for 12 weeks)
Number of subjects: 30
Study 35553855 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 30
Study 35553855 — intervention group
Group type: COMPARATOR
Intervention: Control group (maintained daily lifestyle without training)
Number of subjects: 30
Study 33148767 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic exercise (IDC) - 6 months, three times per week, progressive, moderate intensity
Number of subjects: 124
Study 33148767 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 124
Study 36309399 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-LC
Number of subjects: 200
Study 36309399 — intervention group
Group type: COMPARATOR
Intervention: MC
Number of subjects: 200
Study 34325924 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol maleate 0.5% eye drops from India
Number of subjects: 7
Study 34325924 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol maleate 0.5% eye drops from DRC
Number of subjects: 7
Study 34325924 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol maleate 0.5% eye drops from developing countries (India and DRC)
Number of subjects: 7
Study 32418078 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant transarterial infusion chemotherapy (TAI) with FOLFOX regimen
Number of subjects: 127
Study 32418078 — intervention group
Group type: COMPARATOR
Intervention: Follow-up without any adjuvant treatment (FU group)
Number of subjects: 127
Study 36258223 — intervention group
Group type: EXPERIMENTAL
Intervention: StOP?‐protocol intervention group
Number of subjects: 14000
Study 36258223 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control) group
Number of subjects: 14000
Study 32107337 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m2) given concurrently prior to each infusional EPOCH cycle
Number of subjects: 106
Study 32107337 — intervention group
Group type: COMPARATOR
Intervention: Rituximab (375 mg/m2) given sequentially (weekly for 6 weeks) following completion of EPOCH
Number of subjects: 106
Study 32107337 — intervention group
Group type: EXPERIMENTAL
Intervention: EPOCH chemotherapy (96-hour IV infusion of etoposide, doxorubicin, vincristine plus oral prednisone followed by IV bolus cyclophosphamide every 21 days for 4 to 6 cycles)
Number of subjects: 106
Study 33731656 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Exercise (RE)
Number of subjects: 9
Study 33731656 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Exercise (HIIE)
Number of subjects: 9
Study 33731656 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent Exercise (CE)
Number of subjects: 9
Study 32713846 — intervention group
Group type: EXPERIMENTAL
Intervention: CT colonography (CTC), n=302
Number of subjects: 953
Study 32713846 — intervention group
Group type: COMPARATOR
Intervention: Colonoscopy (CC), n=346
Number of subjects: 953
Study 32713846 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsule endoscopy (CE), n=305
Number of subjects: 953
Study 32713846 — intervention group
Group type: EXPERIMENTAL
Intervention: No investigation
Number of subjects: 953
Study 33399050 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted therapy (RT) with Gloreha device
Number of subjects: 24
Study 33399050 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (CT)
Number of subjects: 24
Study 32203229 — intervention group
Group type: EXPERIMENTAL
Intervention: High-medium glycemic index (hGI) rice (GI: 86)
Number of subjects: 189
Study 32203229 — intervention group
Group type: COMPARATOR
Intervention: Medium-high glycemic index (mGI) rice (GI: 62)
Number of subjects: 189
Study 36124455 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupotomy treatment on pain points around knee joint, once a week for 3 weeks.
Number of subjects: 110
Study 36124455 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib capsule, 200 mg orally once a day for 3 weeks (western medicine group).
Number of subjects: 110
Study 34405978 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbreviated mindfulness practice course
Number of subjects: 108
Study 34405978 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 108
Study 35167364 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi intervention (n=12)
Number of subjects: 24
Study 35167364 — intervention group
Group type: COMPARATOR
Intervention: Usual care control (n=12)
Number of subjects: 24
Study 33236043 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut group (56 g/d as snacks, n=113)
Number of subjects: 224
Study 33236043 — intervention group
Group type: COMPARATOR
Intervention: Control group (isocaloric white rice bars, n=111)
Number of subjects: 224
Study 32645021 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplements
Number of subjects: 0
Study 33739211 — intervention group
Group type: EXPERIMENTAL
Intervention: Early adolescent sexual desire (EASD) measure
Number of subjects: 542
Study 34085476 — intervention group
Group type: EXPERIMENTAL
Intervention: ZHU Lian's type‐Ⅰ inhibition acupuncture combined with Zhuang medicinal thread moxibustion
Number of subjects: 66
Study 34085476 — intervention group
Group type: COMPARATOR
Intervention: Valaciclovir hydrochloride tablets, mecobalamin tablets, and vitamin B1 tablets
Number of subjects: 66
Study 32028286 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day quadruple concomitant regimen
Number of subjects: 364
Study 32028286 — intervention group
Group type: COMPARATOR
Intervention: 14-day quadruple concomitant regimen
Number of subjects: 364
Study 34738660 — intervention group
Group type: EXPERIMENTAL
Intervention: Romosozumab (210 mg sc monthly, n = 17)
Number of subjects: 56
Study 34738660 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (20 μg sc daily, n = 19)
Number of subjects: 56
Study 34738660 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sc monthly, n = 20)
Number of subjects: 56
Study 34289666 — intervention group
Group type: EXPERIMENTAL
Intervention: MicroHeat with endodontic sealer (Mseal)
Number of subjects: 38
Study 34289666 — intervention group
Group type: EXPERIMENTAL
Intervention: MicroHeat without endodontic sealer (Mnoseal)
Number of subjects: 38
Study 34289666 — intervention group
Group type: EXPERIMENTAL
Intervention: System B with endodontic sealer (SBseal)
Number of subjects: 38
Study 34289666 — intervention group
Group type: EXPERIMENTAL
Intervention: System B without endodontic sealer (SBnoseal)
Number of subjects: 38
Study 34289666 — intervention group
Group type: COMPARATOR
Intervention: Positive control (Ct+)
Number of subjects: 38
Study 34289666 — intervention group
Group type: COMPARATOR
Intervention: Negative control (Ct-)
Number of subjects: 38
Study 35645797 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosaprepitant (150 mg)
Number of subjects: 88
Study 35645797 — intervention group
Group type: COMPARATOR
Intervention: Palonosetron (75 μg)
Number of subjects: 88
Study 33016570 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency spinal cord stimulation (10 kHz)
Number of subjects: 126
Study 32828116 — intervention group
Group type: EXPERIMENTAL
Intervention: Low vitamin D3 supplementation (4200 IU/week)
Number of subjects: 80
Study 32828116 — intervention group
Group type: EXPERIMENTAL
Intervention: High vitamin D3 supplementation (28,000 IU/week)
Number of subjects: 80
Study 36074106 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 38
Study 36074106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 33289649 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus axitinib
Number of subjects: 0
Study 33289649 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib monotherapy
Number of subjects: 0
Study 36269291 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback and music training programme (BMT programme)
Number of subjects: 0
Study 36269291 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 32797298 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA (intravenous recombinant tissue-plasminogen activator)
Number of subjects: 1638
Study 32797298 — intervention group
Group type: COMPARATOR
Intervention: No rt-PA
Number of subjects: 1638
Study 34889858 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprostene bunod 0.024%
Number of subjects: 23
Study 33185131 — intervention group
Group type: EXPERIMENTAL
Intervention: increase MVPA intervention
Number of subjects: 204
Study 33185131 — intervention group
Group type: COMPARATOR
Intervention: decrease sedentary behavior active control
Number of subjects: 204
Study 32253894 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal exercise program for 6 months
Number of subjects: 70
Study 32253894 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 70
Study 35108378 — intervention group
Group type: EXPERIMENTAL
Intervention: High Carbohydrate, High Starch (HC-Starch) diet (57% carbohydrate and 25% fat, including 20% refined grains)
Number of subjects: 64
Study 35108378 — intervention group
Group type: EXPERIMENTAL
Intervention: High Carbohydrate, High Sugar (HC-Sugar) diet (57% carbohydrate and 25% fat, including 20% sugar)
Number of subjects: 64
Study 35108378 — intervention group
Group type: COMPARATOR
Intervention: Very-Low-Carbohydrate (VLC) diet (5% carbohydrate and 77% fat)
Number of subjects: 64
Study 35108378 — intervention group
Group type: EXPERIMENTAL
Intervention: High Carbohydrate, High Starch (HC-Starch) and High Carbohydrate, High Sugar (HC-Sugar) diets
Number of subjects: 64
Study 32414335 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD‐10 codes for social anxiety disorder (SAD)
Number of subjects: 95
Study 32414335 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-rater agreement regarding the presence or absence of SAD
Number of subjects: 95
Study 32414335 — intervention group
Group type: EXPERIMENTAL
Intervention: CGI‐S and GAF scores
Number of subjects: 95
Study 32414335 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-rater agreement for CGI‐S and GAF
Number of subjects: 95
Study 36478278 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided percutaneous A1 pulley release
Number of subjects: 84
Study 36478278 — intervention group
Group type: COMPARATOR
Intervention: Classic open surgery
Number of subjects: 84
Study 35595196 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-printed splint (3DPS)
Number of subjects: 34
Study 35595196 — intervention group
Group type: COMPARATOR
Intervention: Conventional removable splint (CRS)
Number of subjects: 34
Study 33729386 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis with alteplase
Number of subjects: 120
Study 33729386 — intervention group
Group type: COMPARATOR
Intervention: Intravenous thrombolysis with batroxobin
Number of subjects: 120
Study 32854478 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal pregnant women)
Number of subjects: 100
Study 32854478 — intervention group
Group type: EXPERIMENTAL
Intervention: Preeclampsia group
Number of subjects: 100
Study 32854478 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS group
Number of subjects: 100
Study 32854478 — intervention group
Group type: EXPERIMENTAL
Intervention: sh‐KCNQ1OT1 group
Number of subjects: 100
Study 32854478 — intervention group
Group type: EXPERIMENTAL
Intervention: miR‐146a‐3p inhibitor group
Number of subjects: 100
Study 32854478 — intervention group
Group type: EXPERIMENTAL
Intervention: sh‐KCNQ1OT1+miR‐146a‐3p inhibitor group
Number of subjects: 100
Study 32208848 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape juice (200-500 mL/day)
Number of subjects: 0
Study 32208848 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-to-moderate wine (1-4 glasses/day)
Number of subjects: 0
Study 32208848 — intervention group
Group type: COMPARATOR
Intervention: Other alcoholic beverages
Number of subjects: 0
Study 32208848 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol (150-1000 mg/day)
Number of subjects: 0
Study 34609549 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab plus remdesivir
Number of subjects: 649
Study 34609549 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus remdesivir
Number of subjects: 649
Study 34279759 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Cognitive-Behavioral Intervention (Healthy Minds) consisting of eight sessions based on cognitive behavioral therapy principles and techniques.
Number of subjects: 30
Study 34279759 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Cognitive-Behavioral Intervention (Healthy Minds)
Number of subjects: 30
Study 34279759 — intervention group
Group type: COMPARATOR
Intervention: Usual services (Control group)
Number of subjects: 30
Study 33599062 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injections every month for a maximum of two sessions
Number of subjects: 25
Study 33027488 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention with serial album
Number of subjects: 90
Study 33027488 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 90
Study 33393736 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark adaptation protocol followed by intense retinal photobleaching
Number of subjects: 20
Study 33393736 — intervention group
Group type: COMPARATOR
Intervention: Constant ambient light without any variation (Control)
Number of subjects: 20
Study 33940637 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast needle acceleration (higher than 1 g)
Number of subjects: 51
Study 33940637 — intervention group
Group type: COMPARATOR
Intervention: Slow needle acceleration (lower than 1 g)
Number of subjects: 51
Study 33448941 — intervention group
Group type: EXPERIMENTAL
Intervention: Air-Fluidized Therapy (AFT)
Number of subjects: 4
Study 33448941 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid Immersion System (FIS)
Number of subjects: 4
Study 35113957 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training (aerobic plus resistance training) for 16 weeks
Number of subjects: 40
Study 35113957 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 33280393 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt surgery (<48 hours)
Number of subjects: 921
Study 33280393 — intervention group
Group type: COMPARATOR
Intervention: Delayed surgery (>48 hours)
Number of subjects: 921
Study 32476054 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal exercise (inclined walking)
Number of subjects: 20
Study 32476054 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal exercise
Number of subjects: 20
Study 32476054 — intervention group
Group type: COMPARATOR
Intervention: Hypercapnia (CO2-control)
Number of subjects: 20
Study 32476054 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased PETCO2 (3-6%)
Number of subjects: 20
Study 35710539 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive medication reduction
Number of subjects: 0
Study 35710539 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 33319495 — intervention group
Group type: EXPERIMENTAL
Intervention: SP (S-1 and cisplatin)
Number of subjects: 110
Study 33319495 — intervention group
Group type: COMPARATOR
Intervention: DP (docetaxel and cisplatin)
Number of subjects: 110
Study 34101780 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 1.2 mg/d + vitamin B12 50 μg/d
Number of subjects: 120
Study 34101780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 32858346 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone 50 mg/d (TRAZ)
Number of subjects: 75
Study 32858346 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep hygiene training (SHT)
Number of subjects: 75
Study 32858346 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep hygiene training and trazodone (SHT + TRAZ)
Number of subjects: 75
Study 32858346 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 75
Study 32858346 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 75
Study 36216827 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib treatment
Number of subjects: 171
Study 36216827 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-angiogenic adjuvant therapy
Number of subjects: 171
Study 33794303 — intervention group
Group type: EXPERIMENTAL
Intervention: End-of-life care staff training intervention (four 4-hour educational workshops on palliative care principles)
Number of subjects: 324
Study 33794303 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 324
Study 33794303 — intervention group
Group type: EXPERIMENTAL
Intervention: End-of-life care staff training intervention
Number of subjects: 324
Study 32011015 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Bone Regeneration (GBR)
Number of subjects: 22
Study 32011015 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous Healing (SH)
Number of subjects: 22
Study 35297582 — intervention group
Group type: COMPARATOR
Intervention: Conventional group (group A: 120 kV, 100 mA)
Number of subjects: 250
Study 35297582 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose group B (100 kV, 100 mA)
Number of subjects: 250
Study 35297582 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose group C (100 kV, 50 mA)
Number of subjects: 250
Study 35297582 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose group D (80 kV, 100 mA)
Number of subjects: 250
Study 35297582 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose group E (80 kV, 50 mA)
Number of subjects: 250
Study 32164877 — intervention group
Group type: EXPERIMENTAL
Intervention: 131I-metuximab (27.75 MBq/kg) administered as a single transarterial injection 4-6 weeks after hepatectomy
Number of subjects: 156
Study 32164877 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant treatment (control group)
Number of subjects: 156
Study 32164877 — intervention group
Group type: EXPERIMENTAL
Intervention: 131I-metuximab
Number of subjects: 156
Study 36130751 — intervention group
Group type: EXPERIMENTAL
Intervention: iSupport intervention
Number of subjects: 350
Study 36130751 — intervention group
Group type: COMPARATOR
Intervention: Standardised information about caring for someone with dementia (control)
Number of subjects: 350
Study 32173259 — intervention group
Group type: EXPERIMENTAL
Intervention: Accumulated walking exercise (APPW) - three 10-min walking bouts after breakfast, lunch, and dinner
Number of subjects: 10
Study 32173259 — intervention group
Group type: EXPERIMENTAL
Intervention: Single bout walking exercise (CPPW) - single 30-min walking bout after dinner
Number of subjects: 10
Study 32173259 — intervention group
Group type: COMPARATOR
Intervention: No-exercise control (NOEX)
Number of subjects: 10
Study 35048745 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasotraline 2 mg/day
Number of subjects: 95
Study 35048745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 33236355 — intervention group
Group type: EXPERIMENTAL
Intervention: SINC feeding protocol
Number of subjects: 80
Study 33236355 — intervention group
Group type: COMPARATOR
Intervention: Standard feeding (Control)
Number of subjects: 80
Study 33547266 — intervention group
Group type: EXPERIMENTAL
Intervention: ET + RT40
Number of subjects: 16
Study 33547266 — intervention group
Group type: COMPARATOR
Intervention: ET + RT20
Number of subjects: 16
Study 33547266 — intervention group
Group type: EXPERIMENTAL
Intervention: RT40 + ET
Number of subjects: 16
Study 33547266 — intervention group
Group type: COMPARATOR
Intervention: RT20 + ET
Number of subjects: 16
Study 32881138 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg/kg ALA
Number of subjects: 180
Study 32881138 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA-treated groups
Number of subjects: 180
Study 35808221 — intervention group
Group type: EXPERIMENTAL
Intervention: Push Band 2.0 (PB2.0)
Number of subjects: 20
Study 35808221 — intervention group
Group type: EXPERIMENTAL
Intervention: OptoJump (OPT)
Number of subjects: 20
Study 35808221 — intervention group
Group type: EXPERIMENTAL
Intervention: Force Plate (FP)
Number of subjects: 20
Study 33674241 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on self-care therapy education
Number of subjects: 267
Study 35979259 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces cerevisiae I-3856 (8 × 10^9 CFU daily)
Number of subjects: 456
Study 35979259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 456